

1 Characterization of Reactive Oxygen Species Signaling changes in a cell culture model of
2 skeletal muscle ageing, and its application to screening pharmacokinetically-relevant
3 exposures of dietary polyphenols for bioactivity.

4 N. Hayes¹, M. Fogarty², L. Sadofsky³, and H.S. Jones^{4*}

5 ¹Department of Biological and Marine Sciences, University of Hull, Hull, HU6 7RX.

6 ²Leeds Trinity University, Leeds, LS18 5HD.

7 ³Centre for Atherothrombotic and Metabolic Research, Hull York Medical School, Hull, HU6
8 7RX.

9 ⁴Institute of Cancer Therapeutics, University of Bradford, Bradford, BD7 1DP.

10 *Corresponding author (h.s.jones@bradford.ac.uk)

11

12 **Data availability statement**

13 The data that support the findings of this study are available from the corresponding author
14 upon reasonable request.

15

16 **Funding statement**

17 NH is supported by a University of Hull-funded PhD studentship. No other funding sources
18 supported this research.

19

20 **Conflict of interest disclosure**

21 There are no conflicts of interest for any of the authors of the manuscript

22

23 **Abstract**

24 Age-related frailty is a significant health and social care burden, however treatment options
25 are limited. There is currently a lack of suitable cell culture model for screening large
26 numbers of test compounds to identifying those which can potentially promote healthy
27 skeletal muscle function. This paper describes the characterization of reactive oxygen and
28 nitrogen species (RONS) signalling changes in young and aged myoblasts and myotubes
29 using the C₂C₁₂ cell line, and the application of aged myoblast and myotube cultures to
30 assess the effect of dietary polyphenols on RONS signalling. Aged myoblasts and myotubes
31 were observed to have significantly increased reactive oxygen species levels (p<0.01 and
32 p<0.001 respectively), increases in nitric oxide levels (p<0.05 for myoblasts and myotubes),
33 and lipid peroxidation markers (p<0.05 for myoblasts and myotubes). A panel of nine
34 polyphenols were assessed in aged myoblasts and myotubes using concentrations and
35 incubation times consistent with known pharmacokinetic parameters for these compounds.
36 Of these, although several polyphenols were seen to reduce single markers of RONS
37 signalling, only kaempferol and resveratrol consistently reduced multiple markers of RONS
38 signalling with statistical significance in both cell models. Overall, this research has shown
39 the utility of the C₂C₁₂ model, as both myoblasts and myotubes, as a suitable cell model for
40 screening compounds for modulating RONS signalling in aged muscle, and that resveratrol
41 and kaempferol (using pharmacokinetically-informed exposures) can modulate RONS
42 signalling in skeletal muscle cells after an acute exposure.

43

44

45 **Introduction**

46 Age-related muscle dysfunction is a major healthcare issue in elderly patient, and is
47 associated with significant reductions in functional capacity, independence, and quality of life
48 (Int. J. Endocrinol., 2021, 5563960). It is also associated with increased risk of chronic
49 debilitating disorders (such as obesity), falls, hospitalization and mortality (Int. J. Endocrinol.,
50 2021, 5563960). Currently, the management of age-related muscle dysfunction consists of

51 diet and lifestyle changes (e.g., increased physical exercise, intake of protein, vitamin D and
52 calcium, weight management), and symptomatic treatments such as pain relief (Ther. Adv.
53 Musculoskelet Dis., 2021, 13, 1759720X211009018). These approaches have had some
54 success in improving patient quality of life, however this outcome is not consistent for all
55 patients (Ther. Adv. Musculoskelet Dis., 2021, 13, 1759720X211009018). Due to the
56 increasing life expectancy, the number of elderly patients suffering with age-related loss of
57 muscle function is predicted to also increase (Int. J. Endocrinol., 2021, 5563960). Thus,
58 identifying new treatments for age-related muscle dysfunction is an important clinical need.

59

60 Reactive oxygen and nitrogen species (RONS) signaling is well-accepted to have important
61 physiological signaling functions in healthy skeletal muscle, and its dysregulation is also
62 strongly implicated in age-related skeletal muscle dysfunction (J. Physiol., 2016, 594, 5081;
63 Biogerontology, 2020, 21, 475). This makes measurements of RONS signaling important
64 biomarkers, and therapeutic targets of skeletal muscle dysfunction. The current state of play
65 in this area has recently been reviewed by Thoma et al (Biogerontology, 2020, 21, 475),
66 highlighting current attempts to modulate RONS signaling have produced mixed results,
67 dependent on the model systems and dosing regimes used (Biogerontology, 2020, 21, 475).

68

69 The dietary polyphenol resveratrol has shown encouraging results in terms of reducing
70 RONS signaling dysfunction and improvement in aged muscle function in both cell culture
71 and mouse models (Sci. Rep., 2015, 28, 8093; J. Nutr. Biochem., 2017, 50, 103; J. Physiol.
72 Sci., 2018, 68, 681). There are some limitations to these studies, particularly the use of
73 supra-physiological concentrations of polyphenols for supra-physiological exposure times,
74 this lack of reflection of the pharmacokinetics of polyphenols is becoming a more recognized
75 issue within dietary polyphenol research (J. Agric. Food Chem., 66, 7857; J. Agric. Food
76 Chem., 66, 8221). Taken together, this suggests that dietary polyphenols such as
77 resveratrol could have therapeutic application to age-related muscle dysfunction, however a
78 more thorough and physiologically-relevant assessment of these compounds needs to be
79 done.

80

81 This study, using the C₂C₁₂ murine myotube model described by Sharples et al (J. Cell.
82 Physiol., 2010, 225, 240), characterizes changes in RONS signaling between young and
83 aged myoblasts and myotubes, which has not been previously reported for this model
84 system. A range of dietary polyphenols, using pharmacokinetics-informed concentrations
85 and exposure durations, were assessed for effects on RONS signaling in aged cells, to
86 identify those which ameliorate age-related changes in these markers. Those polyphenols
87 which alter ROS signaling in the screening assays were then further characterized for effects
88 on ROS signaling in aged myoblasts and myotubes.

89

90 **Materials and Methods**

91 *Materials*

92 All materials were purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated.

93

94 *Cell culture*

95 Murine myoblasts (C₂C₁₂) were purchased from Public Health England at Passage 13 and
96 seeded into either T-75 flasks (Biolite, Thermofisher Scientific), 6 well plates (Biolite,
97 Thermofisher) or 96 well plates (Biolite, Thermofisher Scientific) at a density of 2.75x10⁴
98 cells/cm². Myoblasts were cultured in high glucose Dulbecco's Modified Eagle Medium
99 (DMEM) containing L-glutamine, 10% v/v FBS, 100 U penicillin, 100 µg/mL streptomycin,
100 and 12.5µg/mL amphotericin B, to a confluency of 80%, and reseeded using a 0.5% trypsin
101 solution. To differentiate myoblasts into myotubes, cells were serum-starved (DMEM media

102 containing L- Glutamine, 2% v/v horse serum, 100 U penicillin, 100 µg/mL streptomycin, and
103 12.5µg/mL amphotericin B) for 5-7 days, with media refreshed every 2 days.

104

105 To age myoblast and myotube cultures, myoblasts were continuously cultured for 50
106 population doublings as outlined by Sharples et al 2010. Myoblasts less than passage 20
107 were defined as “young”, with those above passage 30 as “aged”. For aged myotubes,
108 myoblasts were cultured to the appropriate passage number, and were then differentiated as
109 described above.

110

111 *Assessment of myotube length and width*

112 C2C12 myotubes were cultured as described above and imaged by Olympus IX71 Inverted
113 Fluorescence Microscope (10x UPlanXApo Objective), and the thickness of myotubes was
114 determined using the ImageJ software (Version 1.53m). Five 6-well plates were used for
115 each sample group 3 images per well, 5 fibres per image, a mean of three measurements of
116 each myotube diameter was taken and one centermost measurement was taken for length.

117

118

119 *FOX assay*

120 Lysates of myoblasts and myotubes grown in T-75 flasks were prepared after washing
121 cultures with phosphate buffered saline (PBS). Lysates were stored at -20°C until analysed.
122 Cell lysate or hydrogen peroxide standards (80 µL, 0-5 µM) were added into wells of a 96-
123 well plate, with FOX reagent (7.6mg of xylanol orange, 9.8mg of ammonium ferrous sulphate
124 and 1.8217g of sorbitol together in 100ml of 25mM sulphuric acid, 120 µL per well) added to
125 each well, and incubated for 30 minutes in the dark. Absorbance was measured at λ=560
126 nm using a Tecan infinite 200 mx-pro plate reader. Lipohydroperoxide concentrations were
127 calculated for each sample using the hydrogen peroxide standard curve, and then
128 normalized to the protein content of each lysate using Bradford assay.

129

130 *TBARS assay*

131 Lysates of myoblasts and myotubes grown in T-75 flasks were prepared after washing
132 cultures with PBS. Lysate was collected using a cell scraper and suspended in 1.5 mL PBS
133 and stored at -20°C until analysed. The following steps were performed on ice and light
134 shielded wherever possible. 1 mL of cell lysate suspension was added to 100 µL of 6%
135 Perchloric acid (PCA) and incubated for 10 mins, Supernatant was spun off on max speed,
136 4°C for 5 mins. Supernatant was then neutralised with 10 µL of 6 M Potassium Hydroxide
137 Supernatant was spun off on max speed, 4°C for 5 mins and filtered through a 0.22 µm filter.
138 40 µL of sample or 1,1,3,3-Tetraethoxypropane (TEP)/ 40% ethanol standard (0-10 µM)
139 were combined with 200 µL 438 mM Phosphoric acid, 200 µL 41.6 mM Thiobarbituric acid
140 (TBA) and 350 µL 18.2 MΩ Water. Samples and standards were then heated at 90°C for 60
141 mins in the dark. Samples were then transferred to amber HPLC vials and sealed with a
142 crimp top lid.

143 Chromatographic separation was achieved using an Agilent G1311A quaternary pump,
144 Agilent G1367E1260 Infinity High Performance Autosampler and Agilent 1100 Series
145 G1316A COLCOM Column Compartment connected to an Agilent 1260 Infinity
146 Fluorescence Detector. An Agilent ZORBAX Eclipse Plus C18 column (5 µm pore size, 4.6 x
147 250 mm, Agilent Technologies, Cheshire, UK) was used for separating the analytes as
148 detailed below: Solvent A consisted of Phosphate buffer (70% 25 mM KH₂PO₄ : 30% 25 mM
149 Na₂HPO₄) and Solvent B was Acetonitrile. The Column was maintained at 25°C, Flow rate
150 was 1 mL/min, injection volume was 25 µL, starting conditions were equilibrated over 10
151 mins. The method began at 25% Solvent B from 0-1.5 mins, rising to 50% over 1.51-3 mins,
152 holding at 50% until 4 mins then dropping at 4.01 mins, finally holding at 25% until 6 mins.
153 Using FLD λ_{ex} = 532 nm and λ_{em} = 553 nm, TBARS were detected at RT = 3.5 mins.

154

155

156 *DHE assay*

157 Myoblasts and myotubes were cultured in a 96-well plate as described above, leaving the
158 edge wells of the plate free of cells. Once cells had reached the desired confluence or
159 differentiated into myotubes, cell culture media was removed from the wells and replaced
160 with PBS, containing 10 μ M Dihydroethidium (DHE, Abcam, UK, 100 μ L per well). The edge
161 wells were filled with 100 μ L PBS. The well plates also contained cell only control wells (no
162 DHE added), DHE only control wells (no cells), and positive control wells (10 μ M DHE, 1 mU
163 xanthine oxidase, 1 mM xanthine, in PBS). The plate was incubated at 37°C in a BMG
164 Labtech fluorostar omega plate reader, with fluorescence intensity of each well measured
165 each minute (using orbital averaging) for 30 minutes at λ_{ex} 544 nm and λ_{em} 590 nm. At the
166 end of the assay, the wells were emptied and replaced with 100 μ L of PBS, and frozen
167 before quantification of protein content for each well using the Bradford assay. The data
168 was analysed by calculating the linear rate of DHE fluorescence increase for each well,
169 which was then corrected for protein content and the rate of the positive control samples.
170 This was done to ensure reproducibility between different plates and experimental days.

171

172

173 *DCF assay*

174 Myoblasts and myotubes were cultured in a 96-well plate as described above, leaving the
175 edge wells of the plate free of cells. Once cells had reached the desired confluence or
176 differentiated into myotubes, cell culture media was removed from the wells and replaced
177 with PBS, containing 10 μ M Dichlorofluorescein (DCF, Abcam, UK, 100 μ L per well). The
178 edge wells were filled with 100 μ L PBS. The well plates also contained cell only control
179 wells (no DHE added), DHE only control wells (no cells), and positive control wells (10 μ M
180 DCF, 1 mU xanthine oxidase, 1 mM xanthine, in PBS). The plate was incubated at 37°C in
181 a BMG Labtech fluorostar omega plate reader, with fluorescence intensity of each well
182 measured each minute (using orbital averaging) for 30 minutes at λ_{ex} 485 nm and λ_{em} 520
183 nm. At the end of the assay, the wells were emptied and replaced with 100 μ L of PBS, and
184 frozen before quantification of protein content for each well using the Bradford assay. The
185 data was analysed by calculating the linear rate of DCF fluorescence increase for each well,
186 which was then corrected for protein content and the rate of the positive control samples.
187 This was done to ensure reproducibility between different plates and experimental days.

188

189 *DAF assay*

190 Myoblasts and myotubes were cultured in a 96-well plate as described above, leaving the
191 edge wells of the plate free of cells. Once cells had reached the desired confluence or
192 differentiated into myotubes, cell culture media was removed from the wells and replaced
193 with PBS, containing 2 μ M 4,5-Diaminofluorescein diacetate (DAF, Abcam, UK, 100 μ L per
194 well). The edge wells were filled with 100 μ L PBS. The well plates also contained cell only
195 control wells (no DAF added), DAF only control wells (no cells), and positive control wells (2
196 μ M DAF, 10 μ M PAPA NONOate, in PBS). The plate was incubated at 37°C in a TECAN
197 Infinite 200 PRO plate reader, with fluorescence intensity of each well measured each
198 minute (using orbital averaging) for 30 minutes at λ_{ex} 495 nm and λ_{em} 515 nm. At the end of
199 the assay, the wells were emptied and replaced with 100 μ L of PBS, and frozen before
200 quantification of protein content for each well using the Bradford assay. The data was
201 analysed by calculating the linear rate of DAF fluorescence increase for each well, which
202 was then corrected for protein content and the rate of the positive control samples. This was
203 done to ensure reproducibility between different plates and experimental days.

204

205 *PC assay*

206 Dinitrophenylhydrazine (10 mM in 0.5 M phosphoric acid, 100 μ L per well) was added to
207 wells containing 50 μ L of cell lysate (prepared in PBS) and 50 μ L of 18.2 M Ω water and
208 incubated for 10 minutes at room temperature in the dark. To each well, 50 μ L of 6 M
209 sodium hydroxide was added, and the plate was incubated for 10 minutes at room
210 temperature, followed by measurement of absorbance at 450 nm using a Tecan infinite 200
211 mx-pro plate reader. Protein carbonyl concentrations were determined for blank corrected
212 samples using the Beer-Lambert law (molar extinction coefficient = 33131 $M^{-1}cm^{-1}$, followed
213 by normalization to the protein content of each lysate.

214

215 *Bradford assay*

216 Cell lysates (5 μ L per well) were added to a 96 well plate, along with BSA standards (
217 0-1.4 mg/mL in PBS, 5 μ L per well) in triplicate. Bradford reagent (200 μ L per well) was
218 added to these samples and standards and the plate was incubated for 45 minutes in the
219 dark at room temperature. Absorbance at 595 nm was measured using a Tecan infinite200
220 mx-pro plate reader. Protein concentration per μ L of cell lysate was determined for each
221 sample using the calibration curve of BSA standards.

222

223

224 *Statistical analysis*

225 All data was checked for normality of distribution using a Shapiro-Wilks test. Data which
226 was normal was analysed using an independent t-test or one-way ANOVA as indicated in
227 the figure legends. Non-parametric data was analysed using either a Mann-Whitney U or
228 Kruskal-Wallis test as indicated in the figure legends.

229

230

231

232 **Results**


233

234 *Aged myotubes show morphological changes compared to young myotubes*

235 Myotube width and length were compared for young and aged cultures (Figure 1). Aged
236 myoblasts were significantly thinner (Figure 1A, $p < 0.001$, unpaired t-test) and significantly
237 shorter (Figure 1B, $p < 0.001$, Mann-Whitney U test) than young myotubes. This confirmed
238 that, under the culture conditions used in this study, the aged myotubes showed a
239 dysfunctional phenotype compared to young cells.

240

241



242

243 **Figure 1: Effect of ageing protocol on myotube width and length.** Individual replicate
244 experiments are represented by each data-point on the graph, with the median value
245 indicated by the horizontal line. Young and aged datasets were compared using unpaired t-
246 test or Mann-Whitney U test, with **** $p < 0.001$). Panel A shows myotube width (n=15 per
247 group) and panel B shows myotube length (n=15 per group).

248
249

250 *Aged myoblasts show increased markers of RONS and oxidative stress compared to young*
251 *myoblasts*

252 Both young and aged myoblasts were assessed for markers of ROS production, lipid
253 oxidation and protein oxidation (Figure 2). ROS was significantly increased in aged
254 myoblasts compared with young myoblasts by DHE assay (Figure 2A and 1B, $p < 0.01$ and
255 $p < 0.05$ respectively, unpaired t-test). Two markers of lipid oxidation were assessed (FOX
256 assay and TBARS assay), with both markers showing a median increase in aged (compared
257 with young) myoblasts (Figure 2C and D, $p > 0.05$ for FOX assay, $p < 0.05$ for TBARS assay).
258 Protein carbonyls (measured using dinitrophenylhydrazine), as a marker of protein oxidation,
259 showed no differences between young and aged myoblasts (Figure 2E, $p > 0.05$, unpaired t-
260 test). Nitric oxide levels, measured by the DAF assay, were also increased in aged
261 myoblasts compared to young myoblast cultures (Figure 2F, $p < 0.05$, unpaired t-test).

262

263 *Aged myotubes show increased markers of RONS and oxidative stress compared to young*
264 *myotubes*

265 Both young and aged myotubes were assessed for markers of ROS production, lipid
266 oxidation and protein oxidation (Figure 3). ROS was significantly increased in aged
267 myoblasts compared with young myotubes by DHE assay (Figure 3A, $p < 0.001$, unpaired t-
268 test), however this difference was not observed when ROS levels were assessed using the
269 DCF assay (Figure 3B, $p > 0.05$, unpaired t-test). Two markers of lipid oxidation were
270 assessed (FOX assay and TBARS assay), with FOX assay showing a significant increase in
271 aged compared to young, and TBARS assay showing no change in aged (compared with
272 young) myotubes (Figure 3C and D, $p > 0.05$ for FOX assay, $p < 0.05$ for TBARS assay).
273 Protein carbonyls, as a marker of protein oxidation, showed no differences between young
274 and aged myotubes (Figure 3E, $p > 0.05$, unpaired t-test). Nitric oxide levels were also
275 increased in aged myotubes compared to young myotube cultures (Figure 3F, $p < 0.05$,
276 unpaired t-test).

277

278

279 *Screening of polyphenols at physiologically-relevant exposures in aged myoblasts shows*
280 *differential effects on RONS signalling*

281 The dietary polyphenols quercetin, chrysin, curcumin, ellagic acid, kaempferol, resveratrol,
282 epigallocatechin gallate, 3-hydroxy-tyrosol and gallic acid we assessed for effects on ROS
283 levels in aged myoblasts (Figure 4) using the DHE assay. In aged myoblasts, curcumin and
284 kaempferol (at 1 μM , 4 h) significantly reduced ROS production (Figure 4A, curcumin $56\% \pm$
285 4% , kaempferol $54\% \pm 6\%$, $p < 0.05$, Kruskal-Wallis test with Dunn's multiple comparison
286 versus solvent control). ROS production was also reduced by chrysin, ellagic acid and
287 resveratrol, albeit not with statistical significance (Figure 4A).

288

289 Chrysin, curcumin, kaempferol, resveratrol and epigallocatechin gallate (EGCG) were
290 selected for further characterisation, where the effect of exposure to these compounds (at 1
291 μM and 100 nM, 4 h) upon nitric oxide production (Figure 4B) and lipid peroxidation (Figure
292 4C and D) was determined. Nitric oxide production was significantly reduced by both
293 kaempferol (1 μM : $p < 0.0001$; 100 nM: $p < 0.01$) and resveratrol (1 μM : $p < 0.05$; 100 nM:


294 p<0.01, 2-way ANOVA with Tukey's multiple comparisons test). Chrysin (100 nM, 4 h) also
295 approached statistical significance (p=0.052, 2-way ANOVA with Tukey's multiple
296 comparisons test).

297

298 Kaempferol (at 1 μ M and 100 nM, 4 h) and EGCG (100 nM, 4 h) reduced lipohydroperoxide
299 concentrations in aged myoblasts (Figure 4C), however only kaempferol (1 μ M, 4 h) reached
300 statistical significance (p<0.05, 2-way ANOVA with Tukey's multiple comparisons test),
301 whereas 100 nM kaempferol and 100 nM EGCG reached near-significance (p=0.058 and
302 p=0.068 respectively). In the TBARS assay (Figure 4D), significant reductions in lipid
303 peroxidation were observed for chrysin (1 μ M: p<0.01; 100 nM: p<0.05), curcumin (100 nM:
304 p<0.05), kaempferol (1 μ M: p<0.01; 100 nM: p<0.01), and resveratrol (1 μ M: p<0.01; 100
305 nM: p<0.05; all the above significances tested using a 2-way ANOVA with Tukey's multiple
306 comparisons test).


307

308



309
310
311
312
313
314
315
316
317
318

Figure 2: Characterisation of RONS signaling in young and aged myoblasts. Individual replicate experiments are represented by each data-point on the graph, with the median value indicated by the horizontal line. Young and aged datasets were compared using unpaired t-tests, with * $p < 0.05$ and ** $p < 0.01$) Panel A: ROS levels were assessed in young and aged myoblast cultures by DHE fluorescence. Panel B: ROS levels were assessed in young and aged myoblast cultures by DCF fluorescence. Panel C: Lipohydroperoxides were measured by FOX assay. Panel D: Thiobarbituric acid reactive substances were measured by HPLC TBARS assay. Panel E: Protein carbonyls measured using dinitrophenylhydrazine. Panel F: Nitric oxide levels measured using the DAF.



319

320

321

322

323

324

325


326

327

328

Figure 3: Characterisation of RONS signaling in young and aged myotubes. Individual replicate experiments are represented by each data-point on the graph, with the median value indicated by the horizontal line. Young and aged datasets were compared using unpaired t-tests, with ns $p > 0.05$, * $p < 0.05$ and ** $p < 0.01$) Panel A: ROS levels were assessed in young and aged myotube cultures by DHE fluorescence. Panel B: ROS levels were assessed in young and aged myotube cultures by DCF fluorescence. Panel C: Lipohydroperoxides were measured by FOX assay. Panel D: Thiobarbituric acid reactive substances were measured by HPLC TBARS assay. Panel E: Protein carbonyls measured using dinitrophenylhydrazine. Panel F: Nitric oxide levels measured using DAF.

329



330

331

332 **Figure 4: Screening of dietary polyphenols at physiologically-relevant concentrations**
 333 **for effects on ROS production in aged myoblasts, and characterization of hits for**
 334 **effects on lipid peroxidation and nitric oxide levels.** Individual replicate experiments are
 335 represented by each data-point on the graph, with the median value indicated by the
 336 horizontal line. The dashed line on the graphs indicates the solvent control level. Panel A:
 337 The effect of a range of polyphenols (1 μ M, 4 h) on ROS levels was determined using the
 338 DHE assay. Although several polyphenols reduced ROS levels in aged myoblasts, only
 339 curcumin and kaempferol reached statistical significance ($p < 0.05$, Kruskal-Wallis test with
 340 Dunn's multiple comparison versus solvent control). Panel B-D: The effects of selected
 341 polyphenols (1 μ M (circles) or 100 nM (triangles), 4 h) on nitric oxide levels (DAF assay,
 342 Panel B), lipohydroperoxide concentration (Fox assay, Panel C), and TBARS (Panel D) were
 343 determined. Statistical analysis of these data used two-way ANOVA with Tukey's multiple
 344 comparisons test. Statistical significance is indicated in the main text.

345

346

347

348

349

350

351

352

353 *Screening of polyphenols at physiologically-relevant exposures in aged myotubes shows*
354 *differential effects on RONS signalling*

355


356 The dietary polyphenols quercetin, chrysin, curcumin, ellagic acid, kaempferol, resveratrol,
357 epigallocatechin gallate, 3-hydroxy-tyrosol and gallic acid were assessed for effects on ROS
358 levels in aged myotubes (Figure 5) using the DHE assay. In aged myotubes, curcumin and
359 kaempferol (at 1 μ M, 4 h) significantly reduced ROS production (Figure 5A, curcumin 50% \pm
360 9%, kaempferol 49% \pm 2%, $p < 0.05$, Kruskal-Wallis test with Dunn's multiple comparison
361 versus solvent control). ROS production was also reduced by chrysin, ellagic acid and
362 resveratrol, albeit not with statistical significance (Figure 5A).

363

364 Chrysin, curcumin, kaempferol, resveratrol and epigallocatechin gallate (EGCG) were
365 selected for further characterisation, where the effect exposure to these compounds (at 1 μ M
366 and 100 nM, 4 h) upon nitric oxide production (Figure 5B) and lipid peroxidation (Figure 5C
367 and D) was determined. Nitric oxide production was significantly reduced by chrysin (100
368 nM: $p < 0.01$), kaempferol (1 μ M: $p < 0.0001$; 100 nM: $p < 0.0001$) and resveratrol (1 μ M:
369 $p < 0.001$; 100 nM: $p < 0.0001$, 2-way ANOVA with Tukey's multiple comparisons test).
370 Kaempferol (at 1 μ M and 100 nM, 4 h) and resveratrol (100 nM, 4 h) reduced
371 lipohydroperoxide concentrations in aged myoblasts (Figure 5C) with statistical significance
372 (kaempferol 1 μ M: $p < 0.05$; 100 nM: $p < 0.01$; resveratrol 100 nM: $p < 0.05$; 2-way ANOVA with
373 Tukey's multiple comparisons test). In the TBARS assay (Figure 5D), no significant
374 reductions in lipid peroxidation were observed.

375

376



377
378

379 **Figure 5: Screening of polyphenols in aged myotubes for effects on ROS levels, and**
 380 **characterization of hits.** Individual replicate experiments are represented by each data-
 381 point on the graph, with the median value indicated by the horizontal line. The dashed line
 382 on the graphs indicates the solvent control level. Panel A: The effect of a range of
 383 polyphenols (1 μM, 4 h) on ROS levels was determined using the DHE assay. Although
 384 several polyphenols reduced ROS levels in aged myoblasts, only curcumin and kaempferol
 385 reached statistical significance ($p < 0.05$, Kruskal-Wallis test with Dunn's multiple comparison
 386 versus solvent control). Panel B-D: The effects of selected polyphenols (1 μM (circles) or
 387 100 nM (triangles), 4 h) on nitric oxide levels (DAF assay, Panel B), lipohydroperoxide
 388 concentration (Fox assay, Panel C), and TBARS (Panel D) were determined. Statistical
 389 analysis of these data used two-way ANOVA with Tukey's multiple comparisons test.
 390 Statistical significance is indicated in the main text.

391
392

393 Discussion

394 Although oxidative stress endpoints have been previously assessed in C₂C₁₂ cells, this study
 395 is the first (to authors knowledge) to undertake a thorough assessment of RONS signaling
 396 changes between young and aged (by multiple population doublings) myoblast and myotube
 397 cell cultures, and use this model to screen for potential modifiers of RONS signaling
 398 dysfunction in aged skeletal muscle. Previous studies of oxidative stress in C₂C₁₂ have used
 399 a range of stressors such as TNF-α (J Pharm Biomed Anal, 2021, 204, 114271), LPS (Poult
 400 Sci. 2019 Jul 1;98(7):2756-2764), and hydrogen peroxide (J Biosci Bioeng. 2021

401 May;131(5):572-578; *Molecules*. 2021 Jan 4;26(1):215; *J Pharmacol Exp Ther*. 2021
402 Mar;376(3):385-396; *Front Cell Dev Biol*. 2020 Sep 11;8:541260), whereas this study uses
403 repeated population doublings to mimic the ageing process. The C₂C₁₂ model used in this
404 study has been well-characterized in a physiological context (such as alterations to myotube
405 structure, time to differentiation from myoblasts to myotubes, maintenance of a skeletal
406 muscle phenotype, e.g., Sharples et al 2010) to reflect an aged skeletal muscle phenotype,
407 an observation our study agrees with (based on a reduction of myotube length and width
408 compared with young cells, Figure 1), and this study has now demonstrated that it also
409 reflects biochemical alterations in RONS signaling. Increases in ROS levels and markers of
410 lipid oxidation have been shown for both myoblasts and myotubes in aged cultures
411 compared with young cultures, whereas protein carbonyl levels were not different in young
412 and aged cultures (Figures 2 and 3). These observations show good agreement with human
413 biopsy data for studies comparing young and aged volunteers, showing consistent increases
414 in lipid oxidation markers (biopsy data is quite variable for protein carbonyl level, with some
415 studies showing differences and others no changes) supporting the validity of the myoblast
416 and myotube culture models (*Free Rad. Biol. Med.*, 1999, 26, 303; *Redox Biol.*, 2015, 5,
417 267; *Free Rad, Biol. Med.*, 2006, 41, 797). Increases in nitric oxide levels have also been
418 reported in aged skeletal muscle samples from rodent models (e.g., *Free Radic Biol Med*.
419 2015 Jan;78:82-8) and 3-nitrotyrosine (a marker of protein nitrosylation and surrogate
420 marker for nitric oxide) has been reported to increase in human biopsy samples from aged
421 compared with young participants (*Cells* 2019, 8(12), 1525). Taken together, these data
422 suggest that the C₂C₁₂ model used in this study is representative of aged skeletal muscle
423 biopsy samples in both phenotypic and RONS signalling contexts.

424
425 A major limitation of skeletal muscle ageing and sarcopenia research is a lack of a tractable
426 model to screen compounds for potential beneficial effects on muscle ageing and
427 dysfunction. Although there are a range of in vivo model systems (e.g., murine and other
428 rodent models), these lack the throughput and capacity to screen a large number of
429 compounds. This study demonstrates that the C₂C₁₂ ageing model can address this issue.
430 Both aged myoblast and myotube cultures were used as a screening tool to identify dietary
431 polyphenols with bioactivity on RONS signaling from a wider panel of polyphenols. Chrysin,
432 curcumin, kaempferol and resveratrol were identified to reduce elevated markers of RONS
433 levels and lipid peroxidation at physiologically-relevant exposures. This screening approach,
434 combined with the use of compound exposure concentrations and durations guided by
435 known pharmacokinetic parameters for these compounds, are two areas in which this work
436 has advanced the field.

437
438 Resveratrol, curcumin, epigallocatechin gallate and quercetin have all been previously
439 assessed for effects on skeletal muscle aging in cell culture and rodent models (*Int J Mol*
440 *Sci*, 2019, 20, 1178; *J Agric Food Chem*, 2021, 69, 6214; *FASEB*, 2014, 28, 1159.4;
441 *Antioxidants*, 2021, 10, 476; *Protein and Cell*, 2019, 10, 770; *Braz. Pharm Sci*, 2020, 56; *J*
442 *Frail Ageing*, 2015, 4 209; *Exp Gerontol*, 2008, 43, 176; *Arch Biochem Biophys*, 2020, 692,
443 108511; *Biochem and Biophys Res Comm*, 2017, 489, 142). These studies have shown that
444 these polyphenols alter ROS signaling in skeletal muscle cells and lysate, and some, but not
445 all, rodent studies report improvements in muscle function with chronic exposures. A major
446 limitation of these studies is that the in vitro experiments use exposures which do not reflect
447 human pharmacokinetic data (for example, Chang et al exposed C₂C₁₂ cells to 50 µM
448 epigallocatechin gallate for 24 h, whereas the reported C_{max} and half-life for
449 epigallocatechin galate in humans is 447 ± 300 nM and 3.6 ± 1.4 h (*Arch Biochem Biophys*,
450 2020, 692, 108511, *Cancer Epidemiol Biomarkers Prev*. 2002, 1025-32.). Additionally, even
451 the rodent model studies highlighted above use impractical doses of polyphenols when

452 scaled to human studies (for example, both Alm-Eldeen et al. and Meador et al. dosed rats
453 with 200 mg/kg body weight per day, which when scaled to a 75 kg human (as detailed in J
454 Basic Clin Pharm, 2016, 7, 27-31, taking body surface area into consideration) equates to a
455 bolus of 2.43 g of pure quercetin or epigallocatechin gallate per day respectively (Braz.
456 Pharm Sci, 2020, 56; J Frail Ageing, 2015, 4 209). Human clinical trials using quercetin
457 report minor side effects at long term doses over 1g, (J Am Heart Assoc, 2016, 5, e002713),
458 suggesting that the exposures used in the rodent models are not reflective of what would be
459 used in humans. This lack of relevance to human pharmacokinetics in both in vitro and
460 animal model experiments means that it is difficult to extrapolate these findings to humans.
461 Our study has, for in vitro models, used more pharmacokinetically-relevant exposures, using
462 a 4 h exposure at 1 μ M for initial screening, and a lower concentration (100 nM, 4 h) which is
463 also consistent with reported pharmacokinetic data for the test compounds (Cancer
464 Epidemiol Biomarkers Prev. 2008 Jun;17(6):1411-7; Cancer Epidemiol Biomarkers Prev.
465 2002, 1025-32; Br. J. Clin. Pharm., 51 (2) (2001), pp. 143-146; Ann N Y Acad Sci. 2011
466 Jan;1215:9-15; Nutrients 2019, 11(10), 2288). It should be noted that there are some
467 potentially-important limitations with the experimental design in this study. Dietary
468 polyphenols undergo significant conjugative metabolism (e.g., glucuronidation, sulfation,
469 methylation), however due to a lack of availability of human polyphenol metabolites, they
470 were not used in the experiments described in this study. Additionally, the experiments
471 described above assess the effects of acute exposures to dietary polyphenols, whereas a
472 chronic dosing is more likely to be experienced by humans.

473

474

475 **Conclusions**

476 Overall, this study has characterized a myoblast and myotube cell culture model of skeletal
477 muscle ageing for changes in RONS signaling. These cultures show similar changes to
478 those reported for human skeletal muscle biopsies, and the modulation of RONS signaling
479 by physiologically-relevant dietary polyphenol exposures in aged myoblasts and myotubes
480 has been demonstrated. This model system can be used to identify bioactive compounds
481 which may be beneficial for restoring normal RONS signaling in aged skeletal muscle.

482

483

484 **References**

- 485 Int. J. Endocrinol., 2021, 5563960
486 Ther. Adv. Musculoskelet Dis., 2021, 13, 1759720X211009018
487 J. Physiol., 2016, 594, 5081
488 Biogerontology, 2020, 21, 475
489 Sci. Rep., 2015, 28, 8093
490 J. Nutr. Biochem., 2017, 50, 103
491 J. Physiol. Sci., 2018, 68, 681
492 J. Agric. Food Chem., 66, 7857
493 J. Agric. Food Chem., 66, 8221
494 J. Cell. Physiol., 2010, 225, 240
495 J. Gerontol. A Biol Sci Med Sci., 2011, 66, 751
496 Int. J. Clin. Exp. Physiol., 2014, 1, 253
497 Free Rad. Biol. Med., 1999, 26, 303
498 Redox Biol., 2015, 5, 267
499 Free Rad, Biol. Med., 2006, 41, 797
500 Int J Mol Sci, 2019, 20, 1178
501 J Agric Food Chem, 2021, 69, 6214
502 FASEB, 2014, 28, 1159.4

- 503 Antioxidants, 2021, 10, 476
504 Protein and Cell, 2019, 10, 770
505 Braz. Pharm Sci, 2020, 56
506 J Frail Ageing, 2015, 4 209
507 Exp Gerontol, 2008, 43, 176
508 Arch Biochem Biophys, 2020, 692, 108511
509 Biochem and Biophys Res Comm, 2017, 489, 142
510 Cancer Epidemiol Biomarkers Prev. 2002, 1025-32
511 Br. J. Clin. Pharm., 51 (2) (2001), pp. 143-146
512 Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1411-7
513 Br. J. Clin. Pharm., 51 (2) (2001), pp. 143-146
514 Ann N Y Acad Sci. 2011, 1215:9-15
515 Nutrients 2019, 11(10), 2288
516 Protein and Cell, 2019, 10, 770

517

518 **Acknowledgements**

519 NH was funded by a University of Hull PhD studentship. We thank Dr Roger Sturmeay and
520 Mr Andrew Gordon for their assistance with the TBARS assay.

521

522 **Author statements**

523 All the authors declare that there are no conflicts of interest with this research.

524

525 HSJ: Designed the study, planned experiments, analysed data, wrote the manuscript.

526 NH: Designed the study, planned experiments, analysed data, wrote the manuscript.

527 MF: Designed the study, wrote the manuscript

528 LS: Designed the study, wrote the manuscript.

529